awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AE
Q35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AE
How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab
P2860
Q35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35866147-87DC5FAD-7BB1-411E-A027-17BA48F5A6AE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e017ac9e3bdc935bd43984110b53f91d5ba69fae
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.